Loading patent…
AssigneeInstitut Pasteur
InventorsThomas Bourgeron, Jonas Melke, Hany Goubran Botros, Jean-Marie Launay, Marion Leboyer, Christopher Gillberg, Pauline Chaste, Richard Delorme
Estimating the term…
The present invention relates to a method for determining likelihood of an individual of developing a psychiatric disorder. More particularly, the method of the invention is based on the identification of genetic variations in genes involved in the modulation of melatonin and their consequences on such pathway for the determination of whether an individual is susceptible of being afflicted by a psychiatric disorder such as autism spectrum disorders (ASD), Deficits and Hyper Activity Disorder (ADHD) and anorexia.
A method for determining likelihood of an individual of developing a psychiatric disorder, comprising:
26-42. (canceled)
A composition for treating and/or preventing a psychiatric disorder in an individual having a defective gene involved in the modulation of melatonin, comprising an acceptable carrier and a therapeutically effective amount of a molecule promoting melatonin modulation.
A method for treating and/or preventing ASD in an individual comprising the administration in said individual of a composition comprising melatonin or a functional derivative thereof.
An isolated polynucleotide encoding a polypeptide or functional derivative thereof, wherein said polypeptide or functional derivative thereof comprises a point mutation in the amino acid sequence as defined in SEQ ID NO:1.
An isolated polynucleotide encoding a polypeptide or functional derivative thereof, wherein said polypeptide or functional derivative thereof comprises a point mutation in the amino acid sequence as defined in SEQ ID NO:4.
An isolated polynucleotide encoding a polypeptide or functional derivative thereof, wherein said polypeptide or functional derivative thereof comprises a point mutation in the amino acid sequence as defined in SEQ ID NO:5.
An isolated polynucleotide comprising a regulatory sequence of the ASMT gene, wherein said regulatory sequence comprises an insertion/deletion mutation compared to the wild type regulatory sequence of said ASMT gene.
An isolated polynucleotide comprising a regulatory sequence of the AANAT gene, wherein said regulatory sequence comprises an insertion/deletion mutation compared to the wild type regulatory sequence of said AANAT gene.
Dependencies are inferred from the claim text.